The mhGAP guideline has been developed to help countries address the growing challenges of mental, neurological, and substance use (MNS) conditions. With 30 updated and 18 new recommendations in addition to the 90 pre-existing ones, this latest edition is the third iteration of the guideline and reflects years of investment in the mhGAP program.

These revised recommendations are designed to ensure that mhGAP provides non-specialist health workers in low and middle-income countries with high-quality, timely, transparent, and evidence-based guidance to effectively treat and care for individuals with MNS conditions. By providing practical tools and strategies for addressing these challenges, the mhGAP guideline aims to narrow the treatment gap and improve access to care for those who need it most.

The need for improved capacity to address MNS conditions is critical, given their increasing prevalence in many parts of the world. The latest edition of the guideline represents a significant step forward in this effort by providing healthcare professionals with clear guidance on best practices for diagnosing and treating these conditions.

Overall, the mhGAP guideline remains a vital resource for healthcare providers working in low and middle-income countries. With its focus on quality care and evidence-based practice, it continues to support non-specialist health workers in delivering effective treatment and care for individuals with MNS conditions.